News

Serina Therapeutics announces agreement with AstraZeneca for development of polymer


Serina Therapeutics, Inc. has developed a proprietary, patented polymer technology for drug development and announced an agreement with AstraZeneca to develop the polyoxazoline (POZ) polymer therapeutic with an AstraZeneca proprietary compound. The nature of the POZ therapeutic and the terms of the agreement were not immediately disclosed. 

Jeremy Schmutz receives cotton biotechnology award

News Outlet: 
PR Newswire
Date published: 
January 16, 2013

NEW YORK, Jan. 17, 2013 -- As part of the recent Plant and Animal Genomic Conference held in San Diego, Calif., Dr. Don Jones of Cotton Incorporated presented the 2012 Cotton Biotechnology Award to five outstanding researchers that were instrumental in mapping the cotton genome. The diverse and talented team, composed of Dr. Andrew Paterson, Dr. Jonathan Wendel, Mr. Jeremy Schmutz, Dr. Dan Peterson and Dr. Dan Rokhsar, led the collaborative international effort to complete the first "gold standard" Gossypium genome sequence.  

HudsonAlpha partners with city in Healthy Huntsville 2013 campaign

News Outlet: 
The Huntsville Times
Date published: 
January 15, 2013

HUNTSVILLE, Alabama - The Rocket City's battle against bulge is getting serious. On Tuesday, Mayor Tommy Battle announced an expanded Healthy Huntsville campaign designed to help folks slim down and live longer. The city is working with Huntsville Hospital, city schools, the county health department and HudsonAlpha Institute for Biotechnology to offer at least one free, fitness-related event per week in 2013.

Reuters highlights CFDRC in vitro tumor model

News Outlet: 
Reuters
Date published: 
December 11, 2012

 

CFD Research Corporation has been awarded a $1.3 million grant from the National Institutes of Health to develop their novel in vitro tumor model. SynVivo-Tumor replicates the tumor microenvironment with physiologically and morphologically realistic microvasculature including endothelial cell-lined leaky vessels and 3D solid tumors. Tumor drug delivery is a complex phenomenon affected by several elements in addition to physico-chemical properties. 
 
"Current in vitro models of tumor drug delivery are oversimplified and show poor correlation with in vivo performance," said Prabhakar Pandian, Ph.D., CFDRC principal investigator. "Our novel platform mimics the in vivo environment with physiologically relevant flow resulting in endothelial cell lined capillary vessels and 3D solid tumors. Most importantly, the SynVivo-Tumor platform enables real-time, quantitative assessment of the performance of drug delivery vehicles."

Popular Science lists IDair's fingerprint scanner in its "best of" list

News Outlet: 
Popular Science/The Huntsville Times
Date published: 
November 27, 2012

 

Huntsville, Ala. - A Huntsville company whose fingerprint scanner can photographically capture fingerprints from as far as six meters has been named to Popular Science's "Best of What's New" list.
 
The product, AIRprint, is made by IDair, a HudsonAlpha-based spinoff of Advanced Optical Systems. Most of IDair's customers are military, but this summer, a 24-hour fitness center was beta-testing the system as a way to stop people from sharing access keys without paying. The product, according to Popular Science, costs $5,000.
 
Click here to see the follow-up story on this HudsonAlpha resident associate company in the Huntsville Times. To see the product in Popular Science, click here

Study illuminates photosynthesis as an evolutionary process

HudsonAlpha scientists among those examining tiny algae

HUNTSVILLE, Ala - When you think about walking through a tall meadow of grass, you likely envision peace and calm. But on a sunny day those grass blades are busy factories turning light into food energy through a complex mechanism of enzymes arranged in the photosynthetic pathway. Those grass cells can only act as factories because distant ancestors declared war on other cells and swallowed them whole, trapping and forcing them to work for the grass cell.
 


Buttoning up the button mushroom genome

 

HUNTSVILLE, Ala - You may know it as your favorite pizza topping but researchers also know the button mushroom, or Agaricus bisporus, as a known decayer of leaves and other matter along the forest floor. Through an international collaboration including the HudsonAlpha Institute, the U.S. Department of Energy Joint Genome Institute and numerous other research labs, the full genome and gene repertoire for the button mushroom has been completed, giving scientists a better understanding of its full capabilities. 

Study reveals new targets for some cancers of the lymphatic system


HudsonAlpha part of research team
 
HUNTSVILLE, Ala. - HudsonAlpha scientists, in collaboration with Sandeep Dave, M.D., Duke Institute for Genome Sciences and Policy, and other colleagues from leading research institutions across the nation, have found new gene targets for cancer patients with a particular type of non-Hodgkin lymphoma.
 
“By sequencing the exomes, or the 3 percent of the genome which contains genes, in 51 Burkitt lymphoma tumors and eight cell lines, we were able to show 70 other genes were mutated regularly in this tumor type,” said Shawn Levy, Ph.D., faculty investigator at the HudsonAlpha Institute for Biotechnology. “A number of these genes had never previously been shown to be mutated in cancer, so this work gives the scientific community more targets for diagnostics and therapeutics.”

iXpressGenes International Space Station grant featured in The Huntsville Times

News Outlet: 
The Huntsville Times
Date published: 
November 11, 2012

 

HUNTSVILLE, Alabama -- A company at the HudsonAlpha Institute for Biotechnology has won one of the first three grants from the center managing research on the International Space Station for science that could lead to new and more effective medicines. Also funded this month is work being done at the University of Alabama in Birmingham.
 
The Huntsville company, iXpress Genes, Inc., proposes to grow large protein crystals in space for studies that could lead to new understanding of molecules. That understanding is a key to designing new medications that don't cause side effects when they interact with molecules in the body. 

CASIS announces first grants for protein crystallization

iXpress Genes, a HudsonAlpha resident associate company, will have research project on board International Space Station

KENNEDY SPACE CENTER, FL. (November 1, 2012) – The Center for the Advancement of Science in Space (CASIS), the nonprofit organization promoting and managing research on board the International Space Station (ISS) U.S. National Laboratory, today announced its first research grant awards totaling $1.2 million for three projects advancing protein crystallization in microgravity.

click here for the entire release from CASIS

 

Syndicate content